256 citations
,
March 2019 in “Journal of the American Academy of Dermatology” This review provides graded evidence and a therapeutic algorithm for managing hidradenitis suppurativa, but does not present new clinical results.
86 citations
,
June 2018 in “Cochrane library” This review update suggests that mycophenolate mofetil may increase complete disease remission in proliferative lupus nephritis compared to intravenous cyclophosphamide, but with low certainty of evidence.
72 citations
,
July 2022 in “Frontiers in Systems Biology” This review provides a comprehensive guide to the human microbiome and reports no new experimental results; it highlights the impact of modern lifestyles on microbial homeostasis and the necessity of conservation efforts.
71 citations
,
May 2024 in “New England Journal of Medicine” This study investigated the impact of the JAK inhibitor ruxolitinib on APS-1 patients, reporting that treatment decreased excessive T-cell-derived interferon-γ, normalized inflammatory markers, and led to remission of several autoimmune symptoms without serious adverse effects.
47 citations
,
September 2022 in “European Heart Journal” This consensus document reviews current knowledge on sex differences in essential hypertension and identifies areas needing further research to improve sex-specific prevention and management strategies.
47 citations
,
December 2021 in “Applied Sciences” This study demonstrated that Stellaria media extract may enhance wound healing in vitro by promoting cell migration and proliferation, with notable antioxidant and antimicrobial properties.
46 citations
,
October 2018 in “JCI insight” In this study, the researchers found that treatment with the JAK inhibitor tofacitinib in alopecia areata patients may reduce clonal CD8+ T cell expansions but does not eliminate them entirely, which could contribute to disease relapse.
45 citations
,
November 2024 in “International Journal of Molecular Sciences” This review discusses how various nutrients, such as flavonoids, probiotics, and omega-3 fatty acids, may support brain health by targeting stress-related pathways, potentially offering protective effects against neurodegenerative and psychiatric disorders through their roles in oxidative stress reduction and neuroinflammation regulation.
45 citations
,
April 2019 in “International Immunology” This review discusses the mechanisms behind alopecia areata and primary cicatricial alopecia and reports no new clinical results, aiming to guide the development of targeted treatments.
29 citations
,
March 2022 in “Biomedicines” This review discusses recent findings on cellular antioxidant responses to oxidative stress and their implications for treating various human diseases but reports no new clinical results.
29 citations
,
December 2019 in “Transfusion and Apheresis Science” This review discusses platelet-derived bio-products for tissue regeneration in various medical fields and reports no new clinical results; it highlights the need for a standardized classification to compare clinical outcomes effectively.
29 citations
,
June 2016 in “Experimental Dermatology” This study provides suggestive evidence that duplications in the MCHR2 gene may be involved in the pathogenesis of alopecia areata.
23 citations
,
December 2013 in “Journal of Investigative Dermatology Symposium Proceedings” This study highlights rapid advances in alopecia areata treatment following the identification of genetic variants associated with increased disease risk, suggesting potential for precision medicine approaches.
19 citations
,
April 2020 in “Oxidative Medicine and Cellular Longevity” This study provides evidence that Fernblock® upregulates antioxidant pathways in cultured keratinocytes, potentially protecting against damage from fine pollutant particles.
18 citations
,
August 2024 in “eLife” This study investigated immune dysregulation in individuals with Down syndrome and found that treatment with the JAK inhibitor tofacitinib improved skin conditions like alopecia areata and reduced autoimmune markers without severe side effects. Additional research is necessary to understand its broader impacts.
13 citations
,
September 2022 in “Frontiers in immunology” This study found that Ifidancitinib, a JAK1/3 inhibitor, significantly promoted hair regrowth and reduced inflammation in a mouse model of alopecia areata by decreasing pathogenic T cell activity and inducing T cell exhaustion.
12 citations
,
October 2018 in “Journal of Mind and Medical Sciences” This study found that an unhealthy lifestyle, including factors like past smoking and lack of fruit/vegetables in the diet, was associated with an increased risk of metabolic syndrome.
8 citations
,
February 2025 in “Pharmaceuticals” This source reviews the potential of polyphenols as therapeutic and preventive treatments for common skin disorders such as acne, fungal infections, dermatitis, alopecia, and skin cancer, emphasizing their anti-inflammatory and antimicrobial effects and ability to penetrate the skin barrier.
8 citations
,
February 2017 in “International journal of molecular sciences” This study found that the natural extract e-CAF promotes the proliferation and migration of human hair dermal papilla cells in vitro, suggesting potential benefits for skin regeneration and tissue repair.
5 citations
,
December 2021 in “Scientific Reports” In this study, researchers found that in mice, gonadal hormones and biological sex do not affect the expression of SARS-CoV-2 entry proteins ACE-2 and TMPRSS-2 in the respiratory tract, regardless of disease state.
2 citations
,
December 2024 in “eLife” This study observed that individuals with Down syndrome exhibit early immune dysregulation, including multi-organ autoimmunity and hypercytokinemia, and found that the JAK inhibitor tofacitinib showed a good safety profile and reduced skin pathology in a Phase II trial.
1 citations
,
January 2021 in “Journal of the Dermatology Nurses’ Association” This article discusses various dermatological topics from the 2020 Dermatology Nurses' Association annual meeting held online, highlighting updates on skin conditions and treatments without reporting new clinical results.
December 2025 in “Cosmetics” This research identified unique gut microbiota patterns in alopecia areata patients, with potential as diagnostic biomarkers and suggesting avenues for microbiota-focused therapies.
November 2024 in “Aging Cell” In this study, researchers found that treating senescent human dermal papilla cells with dasatinib and quercetin improved their ability to regenerate hair follicles by depleting senescent cells and enhancing inductive potency, suggesting potential clinical applications for senolytic treatments in cell-based hair restoration therapies.
December 2022 in “Dermatology and Therapy” This review discusses the unmet needs and barriers in managing alopecia areata in Latin America, highlighting access constraints and recommending coordinated efforts to improve patient outcomes with promising new treatments.
July 2017 in “Journal of the Dermatology Nurses’ Association” This paper shares personal observations and insights from the 2017 Dermatology Nurses’ Association Convention but reports no new research findings, encouraging participation and reflection among attendees.
10 citations
,
July 2015 in “Current opinion in pediatrics, with evaluated MEDLINE/Current opinion in pediatrics” This review discusses updates in the genetics and clinical understanding of congenital ichthyosis and highlights the addition of N-acetylcysteine and topical enzyme replacement to the treatment options, without providing new clinical results.
January 2010 in “Yearbook of Dermatology and Dermatologic Surgery” Topical latanoprost and bimatoprost ophthalmic solutions don't help eyelash growth in patients with alopecia areata.
77 citations
,
June 2015 in “Nature Reviews Urology” This article reviews the effects of various medications on male fertility, noting that while commonly used drugs can mostly have reversible impacts, conclusive human evidence remains limited.
16 citations
,
March 2016 in “Clinical ophthalmology” In this study, bimatoprost 0.03% was effective and well-tolerated for improving eyelash hypotrichosis in healthy adolescents, but not for those with the condition due to chemotherapy or alopecia areata.